A phase 3b, open-label, randomized, pragmatic study of...

A phase 3b, open-label, randomized, pragmatic study of glecaprevir/pibrentasvir +/− ribavirin (RBV) for HCV genotype 1 subjects who previously failed an NS5A Inhibitor + sofosbuvir (SOF) therapy

Lok, A., Willner, I., Reddy, R., Hassan, M., Hinestrosa, F., Shiffman, M., Sulkowski, M., Brown, R., Morelli, G., Peter, J., Fried, M.W., Vainorius, M., Michael, L., Wang, G., Hu, Y., Kort, J., Nelson
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
68
Language:
english
Journal:
Journal of Hepatology
DOI:
10.1016/S0168-8278(18)30427-6
Date:
April, 2018
File:
PDF, 46 KB
english, 2018
Conversion to is in progress
Conversion to is failed